RXRX Relative Valuation
RXRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RXRX is overvalued; if below, it's undervalued.
Historical Valuation
Recursion Pharmaceuticals Inc (RXRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 28.30 is considered Undervalued compared with the five-year average of -7.83. The fair price of Recursion Pharmaceuticals Inc (RXRX) is between 56.60 to 59.90 according to relative valuation methord. Compared to the current price of 5.39 USD , Recursion Pharmaceuticals Inc is Undervalued By 90.48%.
Relative Value
Fair Zone
56.60-59.90
Current Price：5.39
90.48%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
2.13
P/B
Median3y
3.83
Median5y
3.69
-18.55
FCF Yield
Median3y
-14.37
Median5y
-11.74
Competitors Valuation Multiple
The average P/S ratio for RXRX's competitors is 1218.28, providing a benchmark for relative valuation. Recursion Pharmaceuticals Inc Corp (RXRX) exhibits a P/S ratio of 28.30, which is -97.68% above the industry average. Given its robust revenue growth of 6.89%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Recursion Pharmaceuticals Inc (RXRX) currently overvalued or undervalued?
What is Recursion Pharmaceuticals Inc (RXRX) fair value?
How does RXRX's valuation metrics compare to the industry average?
What is the current P/B ratio for Recursion Pharmaceuticals Inc (RXRX) as of Jul 08 2025?
What is the current FCF Yield for Recursion Pharmaceuticals Inc (RXRX) as of Jul 08 2025?
What is the current Forward P/E ratio for Recursion Pharmaceuticals Inc (RXRX) as of Jul 08 2025?